Regenxbio (RGNX) announced the completion of enrollment in the Atmosphere and Ascent pivotal studies evaluating surabgene lomparvovec in wet age-related macular degeneration using subretinal delivery. Topline data is expected in the fourth quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
- Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
- Regenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trial
- Regenxbio FDA delay ‘not a needle mover,’ says Leerink
- Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay